RXST vs. BHC, EDAP, CLPT, STIM, APYX, BLCO, STAA, WRBY, EYE, and LUCY
Should you be buying RxSight stock or one of its competitors? The main competitors of RxSight include Bausch Health Companies (BHC), Edap Tms (EDAP), ClearPoint Neuro (CLPT), Neuronetics (STIM), Apyx Medical (APYX), Bausch + Lomb (BLCO), STAAR Surgical (STAA), Warby Parker (WRBY), National Vision (EYE), and Innovative Eyewear (LUCY). These companies are all part of the "medical" sector.
Bausch Health Companies (NYSE:BHC) and RxSight (NASDAQ:RXST) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation, profitability and community ranking.
Bausch Health Companies received 315 more outperform votes than RxSight when rated by MarketBeat users. However, 66.67% of users gave RxSight an outperform vote while only 61.90% of users gave Bausch Health Companies an outperform vote.
78.7% of Bausch Health Companies shares are held by institutional investors. Comparatively, 78.8% of RxSight shares are held by institutional investors. 8.1% of Bausch Health Companies shares are held by insiders. Comparatively, 9.4% of RxSight shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Bausch Health Companies has a net margin of -5.07% compared to Bausch Health Companies' net margin of -44.01%. Bausch Health Companies' return on equity of -27.68% beat RxSight's return on equity.
Bausch Health Companies presently has a consensus target price of $11.33, indicating a potential upside of 84.73%. RxSight has a consensus target price of $60.63, indicating a potential upside of 0.44%. Given RxSight's higher probable upside, equities research analysts plainly believe Bausch Health Companies is more favorable than RxSight.
In the previous week, Bausch Health Companies had 9 more articles in the media than RxSight. MarketBeat recorded 13 mentions for Bausch Health Companies and 4 mentions for RxSight. Bausch Health Companies' average media sentiment score of 1.45 beat RxSight's score of 0.00 indicating that RxSight is being referred to more favorably in the news media.
Bausch Health Companies has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500. Comparatively, RxSight has a beta of 1.21, suggesting that its stock price is 21% more volatile than the S&P 500.
RxSight has lower revenue, but higher earnings than Bausch Health Companies. RxSight is trading at a lower price-to-earnings ratio than Bausch Health Companies, indicating that it is currently the more affordable of the two stocks.
Summary
RxSight beats Bausch Health Companies on 10 of the 18 factors compared between the two stocks.
Get RxSight News Delivered to You Automatically
Sign up to receive the latest news and ratings for RXST and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RXST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
